Portfolio Lab

Royalty Pharma plc

  • Stock
  • Ticker RPRX
  • ISIN GB00BMVP7Y09
  • Nasdaq
  • US listing in dollars

Health care · Pharmaceuticals · USA

$68.45 +1.08%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Royalty Pharma plc since 06/2020, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

RPRXGlobal equities (VT)

$10,000 grew to $19,521. Global equities (VT): $14,653.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −49.7% in 12/2024, measured from the peak in 01/2021. It took 61 months to get back to the old peak.

1-year return
+81.4%
5-year return p.a.
+13.1%
Return p.a. since 06/2020
+9.3%
Volatility p.a.
23.7%
Largest decline
−49.7%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue594568579609622631674690
Operating income362534210427388563133411
EBITDA362534211428390564134412
Net income2082393228421529518145
Earnings per share0.470.550.070.660.500.670.040.32
Balance sheet
Total assets18,22317,60818,32319,34719,62119,81519,82019,461
Liabilities7,8807,8208,8209,7269,9069,87910,0349,666
Equity10,3429,7789,4949,6089,7159,9379,7869,795
Cash9291,088632939619586812514
Long-term debt6,6156,6197,0038,5668,5718,5768,5827,591
Cash flow
Operating cash flow743596364703827718728686
Free cash flow743596364703827718728686

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2025 at +55.2%, weakest 2023 at −27.1%. 2 of 5 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
4 Nov 2026$0.32
5 Aug 2026$0.04
6 May 2026$0.67
11 Feb 2026$0.50
5 Nov 2025$0.66
6 Aug 2025$0.07
8 May 2025$0.55
12 Feb 2025$0.47
6 Nov 2024$1.21
8 Aug 2024$0.23
9 May 2024$0.01
15 Feb 2024$1.10

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€35bn
Market cap in trading currency
$38.1bn
Enterprise value
$46.2bn
P/E
44.7
P/S
14.57
P/B
3.89
EV/Sales
17.64
EV/EBITDA
30.8
Earnings yield
2.2%
FCF yield
7.8%

Results (last four quarters)

Revenue
$2.62bn
Gross profit
–
EBITDA
$1.50bn
Net income
$672m
Earnings per share
$1.53
Revenue per share
$4.70
Revenue growth
+13.3%
Earnings growth
−49.1%

Profitability

Gross margin
–
Operating margin
57.1%
Net margin
25.7%
Return on equity
6.9%
Return on assets
3.5%

Balance sheet and cash flow

Cash
$545m
Cash per share
$0.98
Financial debt
$8.59bn
Debt/equity %
88
Current ratio
1.29
Book value per share
$17.59
Operating cash flow
$2.96bn
Free cash flow
$2.96bn

Dividend

Dividend yield
1.69%
Dividend (12 months)
$1.16
Yield (12 months)
1.69%
Payout ratio
76%
Ex-dividend date
13 Nov 2026

Shares and trading

Shares outstanding
557m
Volume
3.53m
Avg. volume 3 months
3.18m
Relative volume
1.1

Price and technicals

Price
$68.45
1 day
+1.1%
52-week high
$70.01
52-week low
$38.09
Distance to 52-week high
−2.2%
Distance to 52-week low
+79.7%
Distance to 50-day line
+9.9%
Distance to 200-day line
+23.9%
RSI (14)
63
Volatility 1M
17.6%

Performance

1 week
−1.2%
1 month
+7.4%
3 months
+11.6%
6 months
+25.6%
YTD
+77.1%
1 year
+77.1%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has RPRX performed since 06/2020?

$10,000 grew to $17,685 by 20 Nov 2026, which is +9.3% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is RPRX?

Volatility was 23.7% per year, measured on monthly returns. The largest decline from a peak was −49.7%, with the low in 12/2024.

How does RPRX compare with a broad equity ETF?

Over the same period Global equities (VT) returned +12.5% per year at 15.1% volatility, RPRX returned +9.3% at 23.7%. The correlation of monthly returns was 0.32; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Why does this page show a US listing?

The figures use the stock's listing traded in the US. On individual days its path differs slightly from the price on the home exchange.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.